Video Experimental Relacionado

Updated: May 3, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Cambios cognitivos y el alelo APOE epsilon 4

Ian J Deary¹, Martha C Whiteman, Alison Pattie

¹Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK. i.dreary@ed.ac.uk

|August 29, 2002

Resumen

La función cognitiva en la vejez varía significativamente. El genotipo de la apolipoproteína E (APOE) influye en el envejecimiento cognitivo normal, independientemente del riesgo de enfermedad de Alzheimer.

Área de la Ciencia:

La neurociencia es la neurociencia.
Genética La genética.
Gerontología Gerontología.

Sus antecedentes:

La función cognitiva muestra una variación significativa en los individuos que envejecen, lo que afecta la independencia y la calidad de vida.
La identificación de los factores que influyen en el envejecimiento cognitivo normal es crucial para comprender los cambios cognitivos relacionados con la edad.
El genotipo de la apolipoproteína E (APOE) es un factor de riesgo conocido para la enfermedad de Alzheimer.

Objetivo del estudio:

Investigar los determinantes del cambio cognitivo normal relacionado con la edad.
Examinar la relación entre el genotipo de la apolipoproteína E (APOE) y los cambios cognitivos desde los 11 a los 80 años en individuos no dementes.

Principales métodos:

Estudio longitudinal utilizando datos de la Encuesta Mental Escocesa de 1932.
Volver a probar a los participantes no dementes a los 80 años para evaluar el cambio cognitivo.
Análisis de la variación cognitiva en relación con el genotipo de la apolipoproteína E (APOE).

Principales resultados:

La variación en el cambio cognitivo no patológico entre los 11 y los 80 años de edad se asocia con el genotipo de la apolipoproteína E (APOE).
El alelo APOE epsilon 4 influye específicamente en el envejecimiento cognitivo normal.
Esta influencia parece ser en parte independiente del papel del gen APOE en la patogénesis de la enfermedad de Alzheimer.

Conclusiones:

El genotipo de la apolipoproteína E (APOE) es un factor significativo en el envejecimiento cognitivo normal.
El efecto del alelo APOE epsilon 4 en el envejecimiento cognitivo puede implicar mecanismos distintos de la enfermedad de Alzheimer.
Se necesita más investigación para dilucidar las vías específicas que median la influencia de APOE en las trayectorias cognitivas.

Más Videos Relacionados

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Videos de Conceptos Relacionados

Comparing Copy Number Variations and SNPs

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...